InflaRx 将来の成長

NasdaqGS:IFRX - アナリストの将来予測と過去の財務データ ( )EUR Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	1	-60	-20	-28	3
12/31/2025	1	-73	-93	-60	3
12/31/2024	0	-57	N/A	-51	3
9/30/2024	0	-57	-48	-48	N/A
6/30/2024	0	-47	-43	-43	N/A
3/31/2024	0	-41	-42	-42	N/A
12/31/2023	0	-43	-38	-38	N/A
9/30/2023	0	-35	-32	-32	N/A
6/30/2023	N/A	-35	-30	-30	N/A
3/31/2023	N/A	-27	-32	-31	N/A
12/31/2022	N/A	-29	-34	-34	N/A
9/30/2022	N/A	-34	-40	-40	N/A
6/30/2022	N/A	-38	-47	-47	N/A
3/31/2022	N/A	-54	-42	-42	N/A
12/31/2021	N/A	-46	-40	-40	N/A
9/30/2021	N/A	-42	-38	-38	N/A
6/30/2021	N/A	-37	-37	-37	N/A
3/31/2021	N/A	-32	-37	-36	N/A
12/31/2020	N/A	-34	-37	-37	N/A
9/30/2020	N/A	-39	-43	-43	N/A
6/30/2020	N/A	-46	-43	-43	N/A
3/31/2020	N/A	-52	-46	-45	N/A
12/31/2019	N/A	-53	-44	-43	N/A
9/30/2019	N/A	-50	-34	-33	N/A
6/30/2019	N/A	-42	-30	-29	N/A
3/31/2019	N/A	-29	-25	-24	N/A
12/31/2018	N/A	-30	-22	-22	N/A
9/30/2018	N/A	-31	-20	-19	N/A
6/30/2018	N/A	-29	N/A	-18	N/A
3/31/2018	N/A	-31	N/A	-15	N/A
12/31/2017	N/A	-24	N/A	-12	N/A
9/30/2017	N/A	-17	N/A	-10	N/A
6/30/2017	N/A	-15	N/A	-8	N/A
3/31/2017	N/A	-12	N/A	-7	N/A
12/31/2016	N/A	-9	N/A	-5	N/A

アナリストによる今後の成長予測

収入対貯蓄率: IFRX今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: IFRX今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: IFRX今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: IFRXの収益 ( 65.8% ) US市場 ( 8.9% ) よりも速いペースで成長すると予測されています。

高い収益成長: IFRXの収益 ( 65.8% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: IFRXの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

InflaRx 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Consensus revenue estimates fall by 72%

Consensus EPS estimates upgraded to €0.69 loss

Consensus revenue estimates fall by 94%

No longer forecast to breakeven

Consensus revenue estimates fall by 13%

No longer forecast to breakeven

Recent updates

InflaRx N.V. Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome

InflaRx N.V. to Report Q3, 2024 Results on Nov 08, 2024

Consensus revenue estimates fall by 72%

New major risk - Financial position

InflaRx N.V. to Report Q2, 2024 Results on Aug 08, 2024

InflaRx (NASDAQ:IFRX) Will Have To Spend Its Cash Wisely

Inflarx’S Gohibic (Vilobelimab) Selected for First Barda-Sponsored Clinical Trial to Evaluate Novel Host-Directed Therapeutics for Acute Respiratory Distress Syndrome (Ards)

InflaRx N.V. Hosts R&D Event Highlighting the Promise of INF904

Consensus EPS estimates upgraded to €0.69 loss

New major risk - Revenue and earnings growth

InflaRx N.V. to Report Q1, 2024 Results on May 08, 2024

InflaRx N.V., Annual General Meeting, Apr 25, 2024

Consensus revenue estimates fall by 94%

No longer forecast to breakeven

InflaRx N.V. to Report Q4, 2023 Results on Mar 21, 2024

InflaRx N.V. Appoints Jan Medina as Head of Investor Relations

Consensus revenue estimates fall by 13%

We're Keeping An Eye On InflaRx's (NASDAQ:IFRX) Cash Burn Rate

InflaRx N.V. Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum

No longer forecast to breakeven

New minor risk - Market cap size

InflaRx N.V. Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904

Inflarx N.V.'S Marketing Authorization Application (Maa) for Vilobelimab for Treatment of Critically Ill Covid-19 Patients Under Review by European Medicines Agency (Ema)

InflaRx (NASDAQ:IFRX) Is In A Good Position To Deliver On Growth Plans

Consensus revenue estimates fall by 68%

Forecast breakeven date moved forward to 2024

Inflarx N.V. Appoints Camilla Chong as Chief Medical Officer, Effective July 1, 2023

Forecast breakeven date moved forward to 2024

Forecast to breakeven in 2025

Consensus revenue estimates increase by 883%, EPS downgraded

We're A Little Worried About InflaRx's (NASDAQ:IFRX) Cash Burn Rate

InflaRx N.V. Announces Details Related to the Design of its Planned Phase III Study with Vilobelimab in Ulcerative PG

InflaRx N.V. Provides Update on Planned Phase Iii Study Design in Pyoderma Gangrenosum with Vilobelimab and Status of Its Eua Application in Critically Ill Covid-19 Patients

InflaRx N.V. announced that it expects to receive $2.5 million in funding from Staidson (Beijing) BioPharmaceuticals Co., Ltd.

Can InflaRx (NASDAQ:IFRX) Afford To Invest In Growth?

Consensus revenue estimates increase by 34%

Consensus revenue estimates increase by 34%

InflaRx N.V. Initiates First-In-Human Study with Small Molecule C5ar Inhibitor Inf904

Inflarx Submits Request for Emergency Use Authorization to US FDA for Vilobelimab for Treatment of Critically III COVID-19 Patients

InflaRx seeks FDA emergency use nod for its treatment for critically ill COVID-19 patients

InflaRx N.V. Announces Vilobelimab Phase III Results in Critically Ill COVID-19 Patients Published in the Lancet Respiratory Medicine

InflaRx reports Q2 results

InflaRx Announces Plans to Apply for Emergency Use Authorization from the US FDA for Vilobelimab for Treatment of Critically III COVID-19 Patients

InflaRx stock rises 13% on plans to file EUA for COVID drug in US for critically ill patients

Here's Why We're Watching InflaRx's (NASDAQ:IFRX) Cash Burn Situation

InflaRx Receives U.S. Food and Drug Administration Fast Track Designation for Treatment of Ulcerative Pyoderma Gangrenosum

InflaRx stock rises 14% as vilobelimab gets FDA fast track status for skin disorder

InflaRx N.V. Provides Development Update for Vilobelimab in Pyoderma Gangrenosum and Severe COVID-19

InflaRx granted FDA Type B meeting to discuss submissions for COVID therapy

No longer forecast to breakeven

Forecast to breakeven in 2024

InflaRx N.V., Annual General Meeting, Apr 28, 2022

Consensus revenue estimates fall by 31%

InflaRx N.V. Announces Encouraging Phase III Topline Results from PANAMO Trial of Vilobelimab in Severe COVID-19 Patients

Is InflaRx (NASDAQ:IFRX) In A Good Position To Deliver On Growth Plans?

Forecast to breakeven in 2024

InflaRx N.V. Reports That It Has Received an Advice Letter from the U.S. Food and Drug Administration Related to Its Phase Iii Program with Vilobelimab

InflaRx N.V. Reports Progress in Ongoing Phase II Clinical Trial with Vilobelimab in Cutaneous Squamous Cell Carcinoma

InflaRx N.V Announces New Pipeline Program – Oral C5aR Inhibitor

InflaRx N.V. Initiates Phase III Clinical Program with Vilobelimab in Hidradenitis Suppurativa

Our First Look At InflaRx

Estimating The Fair Value Of InflaRx N.V. (NASDAQ:IFRX)

Independent Non-Executive Director Lina Ma has left the company

InflaRx N.V. to Proceed with Pivotal Development for Vilobelimab in Hidradenitis Suppurativa with New Primary Endpoint

InflaRx (NASDAQ:IFRX) Is In A Good Position To Deliver On Growth Plans

InflaRx And Vilobelimab In AAV: Avoiding Clinical Hard Knocks

InflaRx Announces Positive Data from Second Interim Analysis of Ongoing Phase IIa Open Label Study with Vilobelimab in Pyoderma Gangraenosum

Consensus forecasts updated

Inflarx Doses First Patient in Multicenter Phase Ii Clinical Trial in Cutaneous Squamous Cell Carcinoma with Vilobelimab